Partnership between academia and industry for drug discovery in Alzheimer's disease.
Drug discovery has traditionally been almost exclusively the purview of pharmaceutical and biotechnology companies, whereas universities have focused on basic research. However, given the challenges involved in discovering and developing truly effective, symptomatic treatments and disease-modifying drugs for Alzheimer's disease, there is a need to reassess this simple division of labor. Whereas each sector is likely to retain a core interest and expertise at either end of the drug discovery spectrum, there is room for closer cooperation at the intersection of the for-profit and not-for-profit sectors. The Alzheimer's Association Research Roundtable convened a meeting of senior industry researchers and academic investigators to discuss this intersection and to assess the opportunity for closer partnership on Alzheimer's disease drug discovery and development.
Ivinson
Adrian J
AJ
Harvard NeuroDiscovery Center, Harvard Medical School, Boston, MA, USA.
Lane
Roger
R
May
Patrick C
PC
Hosford
David A
DA
Carrillo
Maria C
MC
Siemers
Eric R
ER
D000046:Academic Medical Centers; D000544:Alzheimer Disease / Q000188:drug therapy*; D000818:Animals; D002986:Clinical Trials as Topic; D015195:Drug Design; D004345:Drug Industry; D006801:Humans; D007373:Interinstitutional Relations